VNDA$7.45
$7.48
Chart
Performance
Key Stats
AI VNDA Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
NeutralVanda Pharmaceuticals (VNDA) shows mixed signals. While it has a significant market presence and a diverse pipeline, recent performance and profitability metrics are concerning. The current valuation and technical indicators suggest a neutral outlook.
Thematic
Vanda Pharmaceuticals operates in the biopharmaceutical sector with a focus on unmet medical needs. Its product portfolio targets specific disorders, and its pipeline includes treatments for various conditions. The thematic strength is moderate, dependent on the success of its pipeline and market adoption.
Fundamental
Vanda Pharmaceuticals exhibits weak profitability and negative earnings trends, with recent quarters showing significant net losses. While revenue has been somewhat stable, the company is not effectively converting it into profit. The balance sheet appears relatively healthy with substantial cash, but debt levels are moderate.
Technical
The stock price is trading below key longer-term moving averages, indicating a downward trend. While some shorter-term indicators show slight upward momentum, overall technicals suggest caution and potential for further downside or sideways movement.
| Factor | Score |
|---|---|
| Biopharmaceutical Innovation | 75 |
| Market Specialization | 70 |
| Regulatory Landscape | 65 |
| Healthcare Spending Trends | 60 |
| Drug Development Risks | 50 |
| Factor | Score |
|---|---|
| Valuation | 50 |
| Profitability | 10 |
| Growth | 40 |
| Balance Sheet Health | 85 |
| Cash Flow | 20 |
| Factor | Score |
|---|---|
| Trend Analysis | 40 |
| Momentum | 50 |
| Volume Confirmation | 60 |
| Support & Resistance | 70 |
| Short-term Moving Averages | 45 |
AI Investing Checklist
Powered by LiveAIBullish Points (6)
Improving EPS Trends
Recent quarterly EPS reports show a trend of beating analyst estimates, with the latest quarter (2025 Q2) reporting actual EPS of -0.08 against an estimate of -0.6, a significant positive surprise of 25.0% (2024Q4 also beat estimates by 44.9%).
Potential for Value Appreciation
The stock's Price-to-Sales (P/S) ratio has been volatile but shows a quarterly P/S of 5.4 in Q1 2025, which, when compared to historical P/S ratios (e.g., 2021 P/S of 3.4), might suggest room for price adjustment if sales growth continues.
Bearish Points (8)
Negative Earnings and Net Margins
The company has consistently reported negative EPS (e.g., -0.76 TTM) and negative net income (e.g., -$18.9 million in 2024), with negative net margins (e.g., -9.5% in 2024), indicating ongoing profitability challenges.
High Valuation Multiples Relative to Earnings
The Price-to-Earnings (P/E) ratio is negative or very high (e.g., -7.0 TTM, 111.3 in 2023), suggesting the stock is either not profitable or is trading at a premium that is not supported by current earnings.
Calendar
July 2025
31
Next Earnings Date
H: $
A: $
L: $
H: 57.00M
A: 54.77M
L: 53.00M
Profile
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Ponvory for the treatment of psoriasis and ulcerative colitis. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) a LAI formulation to treat schizophrenia; Bysanti for the acute treatment of bipolar I disorder, schizophrenia, and major depressive disorder; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, and atopic dermatitis. The company's pipeline products also include Imsidolimab, an IL-36R antagonist, for the treatment of generalized pustular psoriasis; VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; VPO-227 for the treatment of secretory diarrhea disorders comprising cholera; Antisense oligonucleotide molecules, including VCA-894A for the treatment of Charcot-Marie-Tooth Disease and Type 2S (CMT2S); and VGT-1849A for the treatment of polycythemia vera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Seasonals
Price Target
12.67 USD
The 39 analysts offering 1 year price forecasts for VNDA have a max estimate of 20.00 and a min estimate of 5.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Leading developer of CNS therapeutics, including an antipsychotic drug (Caplyta) that directly competes with Vanda's Fanapt in the schizophrenia market.
Weight: 90
Specializes in neurological and psychiatric disorders, with products like Nuplazid and a pipeline targeting conditions similar to Vanda's focus areas, including psychosis and depression.
Weight: 90
A leading company in sleep medicine with established products like Xyrem and Xywav, making them a direct peer and competitor in the sleep-wake disorder market, similar to Vanda's Hetlioz.
Weight: 90
Highly focused on developing and commercializing treatments for rare neurological disorders, particularly sleep-wake disorders (e.g., Wakix), making them a direct competitor to Vanda's Hetlioz.